Нажмите на эту строку чтобы перейти к Новостям сайта "Русский врач"

Перейти
на сайт
журнала
"Врач"
Перейти на сайт журнала "Медицинская сестра"
Перейти на сайт журнала "Фармация"
Перейти на сайт журнала "Молекулярная медицина"
Перейти на сайт журнала "Вопросы биологической, медицинской и фармацевтической химии"
Журнал включен в российские и международные библиотечные и реферативные базы данных

ВАК (Россия)
РИНЦ (Россия)
Эко-Вектор (Россия)

IN VITRO PERMEABILITY STUDY OF NASAL MEDICINAL PRODUCT FOR SYSTEMIC ACTION

DOI: https://doi.org/10.29296/25877313-2024-05-02
Issue: 
5
Year: 
2024

I.V. Vlasenko
General Director,
Ferring Production LLC (Moscow, Russia)
Julietvlasenko@gmail.com; ORCID 0000-0003-3830-8310

For systemic medicinal products bioavailability is a fundamental characteristic that determines their efficacy and onset of action. Biopharmaceutical parameters of nasal preparations (physicochemical properties of the active substance such as membrane permeability, solubility, lipophilicity, pKa, polymorphic state, type of finished dosage form, pH, osmolarity, composition and characteristics of excipients), affecting bioavailability, are variable and controllable within pharmaceutical development. Besides the use of components that affect enzymatic activity, mucoadhesion and effective con-tact time, mucociliary clearance and viscosity of mucous secretion, changing the rate and degree of absorption of the active substance is possible by modulation of tight junctions and paracellular transport. These processes can be particularly determined by the osmolarity of the dosage form and the use of permeation enhancers. Taking into account the portfolio of excipients available to scientists used in a wide range of concentrations, and, in addi-tion, the requirements of the target product profile in terms of safety and pharmacokinetic parameters, as well as regulatory recommendations for jus-tification of the composition within pharmaceutical development, with particular emphasis on the selection of functional components and the concen-trations used, it is important to have relevant and reliable screening tools when formulating a drug product. Due to the absence of standard bioavailabil-ity assessment methods for nasal preparations, literature review was conducted and methodology of in vitro permeability study for of nasal medicinal products for systemic action with the use of artificial membranes as well as cell line RPMI 2650 of human nasal epithelium is developed. The use of such sufficiently homogeneous barrier films allows to minimize the variability of test conditions. Permeation study of developed compositions of an-timigraine medicinal product is conducted. The results obtained provide evidence of their qualitative compliance and allow to recommend laboratory permeability study on cellulose membranes for the selection and justification of the composition of pharmaceutical compositions. Bioavailability is a fundamental characteristic of pharmaceutical products for systemic action, which defines efficacy and speed of action. Permeability through biological membranes is defined not only by the properties of active component but also by the particulars of formulation. Due to the absence of standard bioavailability assessment methods for nasal preparations, literature review was conducted and methodology of in vitro permeability study for of nasal medicinal products for systemic action with the use of artificial membranes as well as cell line RPMI 2650 is developed. Permeation study of developed compositions of antimigraine medicinal product is conducted. The results obtained provide evidence of their qualitative compliance and allow to recommend laboratory permeability study on cellulose membranes as a screening tool in pharmaceutical development.

Keywords: 
permeability study
nasal spray
cell lines
medicinal products
pharmaceutical development.

References: 
  1. EMA/CHMP/QWP/911254/2011 Guideline on quality of trans-dermal patches. Режим доступа: https://www.ema.eu-ropa.eu/en/documents/scientific-guideline/draft-guideline-quality-transdermal-patches_en.pdf (дата обращения / accessed: 05.04.2024)
  2. Inoue D., Furubayashi T., Tanaka A. et. al. Quantitative estimation of drug permeation through nasal mucosa using in vitro membrane permeability across Calu-3 cell layers for predicting in vivo bioa-vailability after intranasal administration to rats. European Journal of Pharmaceutics and Biopharmaceutics. 2020;149:145–153. DOI: 10.1016/j.ejpb.2020.02.004.
  3. Bartos C., Szabó-Révész P., Horváth T. et. al. Comparison of Modern in vitro Permeability Methods with the Aim of Investiga-tion Nasal Dosage Forms. Pharmaceutics. 2021;13(6):846. DOI: 10.3390/pharmaceutics13060846.
  4. Zhang H., Lin C.W., Donovan M.D. Correlation between Nasal Membrane Permeability and Nasal Absorption Rate. AAPS PharmSciTech. 2013;14(1):60–63. DOI: 10.1208/s12249-012-9884-2.
  5. Belgamwar S.V., Patel H.S., Joshi A.S. et. al. Design and develop-ment of nasal mucoadhesive microspheres containing tramadol HCl for CNS targeting. Drug Delivery. 2011;18(5):353–360. DOI: 10.3109/10717544.2011.557787.
  6. Bhanushali R.S., Bajaj A.N. Design and development of ther-moreversible mucoadhesive microemulsion for intranasal delivery of sumatriptan succinate. Indian J Pharm Sci. 2007;69(5):709–712. DOI: 10.4103/0250-474X.38487.
  7. Bartos C., Ambrus R., Kovács A. et. al. Investigation of Absorption Routes of Meloxicam and Its Salt Form from Intranasal Delivery Systems. Molecules. 2018;23(4):784. DOI: 10.3390/molecules23040784.
  8. Naik A., Nair H. Formulation and Evaluation of Thermosensitive Biogels for Nose to Brain Delivery of Doxepin. Biomed Res Int. 2014:847547. DOI: 10.1155/2014/847547.
  9. Shah S.S., Gohil D.Y., Pandya D.N., Meshram D.B. Preparation and evaluation of spray-dried mucoadhesive
  10. microspheres for intranasal delivery of prochlorperazine using fac-torial design. Asian Journal of Pharmaceutics. 2015;9(3):178–189. DOI: 10.4103/0973-8398.160314.
  11. Tas C., Ozkan C.K., Savaser A. et. al. Nasal administration of metoclopramide from different dosage forms: in vitro, ex vivo, and in vivo evaluation. Drug delivery. 2009;16(3):167–175. DOI: 10.1080/10717540902764172.
  12. Basu S., Bandyopadhyay A.K. Development and Characterization of Mucoadhesive in situ Nasal Gel of Midazolam Prepared with Fi-cus carica Mucilage. AAPS PharmSciTech. 2010;11(3):1223–1231. DOI: 10.1208/s12249-010-9477-x.
  13. Hasçiçek C., Gönül N., Erk N. Mucoadhesive microspheres con-taining gentamicin sulfate for nasal administration: preparation and in vitro characterization. Farmaco. 2003;58(1):11–16. DOI: 10.1016/S0014-827X(02)00004-6.
  14. Henriques P., Bicker J., Carona A. et. al. Amorphous nasal powder advanced performance: in vitro/ex vivo studies and correlation with in vivo pharmacokinetics. J. Pharm. Investig. 2023;53(5):723–742. DOI: 10.1007/s40005-023-00630-1.
  15. Werner U., Kissel T. Development of a Human Nasal Epithelial Cell Culture Model and Its Suitability for Transport and Metabo-lism Studies Under in Vitro Conditions. Pharm. Res. 1995;12(4):565571. DOI: 10.1023/A:1016210231121.
  16. Werner U., Kissel T. In vitro Cell Culture Models of the Nasal Epi-thelium: A Comparative Histochemical Investigation of Their Suita-bility for Drug Transport Studies. Pharm. Res. 1996;13(7):978–988. DOI: 10.1023/A:1016038119909.
  17. Schmidt M.C., Peter H., Lang S.R. et. al. In vitro cell models to study nasal mucosal permeability and metabolism. Adv Drug Del Rev. 1998;29(1-2):51–79. DOI: 10.1016/S0169-409X(97)00061-6.
  18. Sarmento B., Andrade F., Baptista da Silva S. et. al. Cell-based in vitro models for predicting drug Permeability. Expert Opin Drug Metab Toxicol. 2012;8(5):607–621. DOI: 10.1517/17425255.2012.673586.
  19. Srinivasan B., Kolli A.R., Esch M.B. et. al. TEER Measurement Techniques for in vitro Barrier Model Systems. J Lab Autom. 2015;20(2):107–126. DOI: 10.1177/2211068214561025.
  20. Gonçalves V.S.S., Matias A.A., Poejo J. et. al. Application of RPMI 2650 as a cell model to evaluate solid formulations for intranasal de-livery of drugs. International Journal of Pharmaceutics. 2016;515(1):1–10. DOI: 0.1016/j.ijpharm.2016.09.086.